ArticleIranian journal of biotechnology2025
Biotechnological Insights into LncRNA-STAT3 Interactions: A Novel Diagnostic Biomarker for Myocardial Hypertrophy.
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long non-coding RNAs as molecular hubs integrating inflammatory and osteogenic pathways in calcific aortic valve disease.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advances in molecular biology have highlighted the significant role of long non-coding RNAs (lncRNAs) in cardiovascular diseases, including myocardial hypertrophy (MH). This study integrates bioinformatics analysis with molecular validation to investigate the regulatory mechanism of lncRNA ENST00000500113.1 on STAT3 expression, aiming to identify novel biomarkers for MH diagnosis. Objectives: We aimed to explore differential expression patterns of lncRNAs and mRNAs in myocardial hypertrophy using biotechnological approaches and establish their potential as diagnostic and therapeutic targets. The study aims to provide actionable insights that can facilitate the development of biotechnological tools for early diagnosis and intervention in myocardial hypertrophy. Materials and Methods: Myocardial tissues from organ donor patients were classified into control and hypertrophy groups. RNA sequencing was performed to identify differentially expressed genes. Advanced bioinformatics techniques were applied for functional enrichment analysis and co-expression network construction. Validation was conducted using qRT-PCR and immunohistochemistry. Results: Bioinformatics analyses revealed that MH-associated mRNAs were enriched in immune system processes and the JAK/STAT signaling pathway. Downregulation of lncRNA ENST00000500113.1 in MH tissues was correlated with upregulated STAT3 expression. Molecular validation confirmed a significant association between ENST00000500113.1 and STAT3, suggesting a regulatory mechanism contributing to MH progression. Conclusions: This study demonstrated the biotechnological potential of integrating bioinformatics and molecular validation to identify lncRNA ENST00000500113.1 as a novel diagnostic biomarker for MH. These findings offer actionable insights into MH pathophysiology and facilitate the development of targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.